As per the license agreenent signed between the two companies in 2004 agreement, they will share all data and associated know-how of the MN-221 development program.
MN-221 is an intravenous drug which is beta (2)-adrenergic receptor agonist.
MediciNova has completed several Phase 1 and 2a trials and is currently conducting a Phase 2b study in patients with acute exacerbations of asthma.
The Phase 2b data showed improvements in FEV1 in all asthma trials as well as a 45% decrease in the hospitalization rate.
MediciNova also completed a Phase 1b clinical study of MN-221 in patients with stable, moderate to severe COPD in which MN-221 demonstrated clinically significant improvements in FEV1 with no clinically relevant safety concerns.